Hyun Ho Choi

USPTO Granted Patents = 71 (Patent Applications = 10)

EPO Patents = 16 (Patent Applications = 6)

Average Co-Inventor Count = 5.2

ph-index = 5

Forward Citations = 121(Granted Patents)

Forward Citations (Not Self Cited) = 101(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Daejeon, KR (2012 - 2014)
Suwon-si, JP (2014)
Gyeonggi-do, KR (2011 - 2015)
Suwon, KR (2013 - 2017)
Yongin-si, KR (2012 - 2022)
Suwon-si, KR (2011 - 2023)

Company Filing History:

59 out of 131,744

Samsung Electronics Co., Ltd.

patents

15 out of 2,619

Korea Advanced Institute of Science and Technology

Samsung Electro-mechanics Co., Ltd.

patents

5. 1 out of 1,245

Sungkyunkwan University

where one patent can have more than one assignee

Years Active: 2011-2023

Loading Chart...

Areas of Expertise:

Triazolopyridin Compounds

Triazolone Derivatives

FGF21 Fusion Proteins

Pharmaceutical Compositions

Semiconductor Processing

Cognitive Radio Communication

Interference Control

Wireless Networks

Multi-Cell Communication

Beamforming Techniques

Hierarchical Cell Communication

Cooperative Communication

71 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11820769 - Triazolopyridin-3-ones or their salts and pharmaceutical compositions comprising the same (2023-11-21),

2. 11780830 - Triazolone derivatives or salts thereof and pharmaceutical compositions comprising the same (2023-10-10),

3. 11713308 - 3,3-difluoroallylamines or salts thereof and pharmaceutical compositions comprising the same (2023-08-01),

4. 11527427 - Semiconductor processing apparatus and semiconductor processing system (2022-12-13),

5. 11492335 - Aryl or heteroaryl triazolone derivatives or salts thereof, or pharmaceutical compositions comprising the same (2022-11-08),

6. 11179440 - Pharmaceutical composition containing FGF21 mutant fusion protein and method for treating hepatitis, hepatic fibrosis, and hepatic cirrhosis (2021-11-23),

7. 11168073 - 3,3-difluoroallylamines or salts thereof and pharmaceutical compositions comprising the same (2021-11-09),

8. 11142557 - Long-acting FGF21 fusion proteins and pharmaceutical composition comprising same (2021-10-12),

9. 11136364 - Dual function proteins comprising FGF21 mutant protein and pharmaceutical composition comprising same (2021-10-05),

10. 11091479 - Triazolopyridin-3-ones or their salts and pharmaceutical compositions comprising the same (2021-08-17),

11. 10995086 - Triazolone derivatives or salts thereof and pharmaceutical compositions comprising the same (2021-05-04),

12. 10899719 - Aryl or heteroaryl triazolone derivatives or salts thereof, or pharmaceutical compositions comprising the same (2021-01-26),

13. 10562865 - Aryl or heteroaryl triazolone derivatives or salts thereof, or pharmaceutical compositions comprising the same (2020-02-18),

14. 9571177 - Communication method of macro base station, macro terminal, micro base station, and micro terminal for interference control in hierarchical cellular network (2017-02-14),

15. 9445423 - Communication method of a base station and a terminal (2016-09-13),

Sure, here is the article:

Title: Hyun Ho Choi: A Trailblazer in Innovation and Technology

Introduction:

Hyun Ho Choi, a distinguished inventor based in Suwon-si, South Korea, has left an indelible mark in the realm of innovation with his remarkable achievements. With a staggering 71 patents to his name, Choi is a true visionary with a penchant for pushing the boundaries of what is achievable in the technology sector.

Latest Patents:

Choi's latest patents include groundbreaking technologies such as Triazolopyridin-3-ones and Triazolone derivatives, which have significant implications in the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH). These inventions highlight Choi's expertise in developing novel pharmaceutical compositions with a focus on VAP-1 inhibitory activity.

Career Highlights:

Throughout his illustrious career, Hyun Ho Choi has made significant contributions to renowned companies such as Samsung Electronics Co., Ltd. and the Korea Advanced Institute of Science and Technology. His innovative spirit and dedication to excellence have propelled him to the forefront of technological advancement, earning him a reputation as a trailblazer in the industry.

Collaborations:

Choi's collaborative work with esteemed colleagues such as Kyung Hun Jang and Hyo Sun Hwang has further enhanced his innovative capabilities. Through synergistic teamwork and shared expertise, Choi and his coworkers have been able to bring cutting-edge technologies to the forefront of the market, solidifying their position as leaders in the field.

Conclusion:

In conclusion, Hyun Ho Choi stands as a true pioneer in the world of innovation, with a track record of success that speaks for itself. His relentless pursuit of excellence and passion for pushing the boundaries of what is possible make him a force to be reckoned with in the world of technology. Choi's groundbreaking inventions have not only revolutionized the field of pharmaceuticals but have also paved the way for future advancements in the industry. It is clear that Hyun Ho Choi's contributions will continue to shape the landscape of innovation for years to come.

This text is generated by artificial intelligence and may not be accurate.